Posts Tagged ‘china-based’
3SBio ties up with Ascentage Pharma to develop & commercialize cancer therapeutics (PharmaBiz)
15 Feb 20103SBio Inc, a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia in China.
About Biolexis
Biolexis is a premiere online resource for life sciences professionals, investors and entrepreneurs. The site offers personalized information biotechnology news and other biotechnology resources. Information is further organized by industry sector, therapeutic areas, technology focus, service orientation, and location. With Biolexis, you can: access over 5,000 biotechnology news strories and biotechnology articles. Search biotech company information, biotech news, biotech articles and biotech related press releases.
Biotech
Categories
- Biotechnology News (1306)
Archives
- How to Train your Brain to keep you healthy and happy
- What makes you unique? Not genes so much as surrounding sequences, study finds
- How to Choose the Correct Workbenches For Your Organization’s Needs
- http://f-cup-products.blogspot.com/2010/03/puera-panic-sos-405mg-x-15-tablets-38.html
- A First: Microchips in living cells
- Enzyme Handbook: Volume 14: Class 2.7 – 2.8 Transferases EC 2.7.105 – EC 2.8.3.14
- Class 2 Transferases X: EC 2.7.1.113 – 2.7.5.7
- Seth Klarman’s Baupost Group Wins Big With Facet Biotech (FACT), Sells Some Shares
- The truth about health insurance profits
- Breaking down a three-tiered option play on the biotechnology concern (Schaeffers Research)
